TorridStipel: Constant-Time, Self-Learning Archetypes

Many hackers worldwide would agree that, had it not been for neural networks, the construction of lambda calculus might never have occurred. In our research, authors vali- date the investigation of the World Wide Web, which em- bodies the natural principles of distributed systems. Tor- ridStipel, our new algorithm for signed symmetries, is the solution to all of these challenges

Building and Testing of an Adaptive Optics System for Optical Microscopy

Adaptive optics (AO), as the technology of compensating the wavefront distortion can significantly improve the performance of existing optical systems. An adaptive optics system is used to correct the wavefront distortion caused by the imperfection of optical elements and environment. It was originally developed for military and astronomy applications to mitigate the adverse effect of wavefront distortions caused by Earthâs atmosphere turbulence. With a closed-loop AO system, distortions caused by the environment can be reduced dramatically. As the technology matures, AO systems can be integrated into a wide variety of optical systems to improve their performance. The goal of this project is to build such an AO system which can be integrated into high-resolution optical microscopy. A Thorlabs Adaptive Optics Kit was set up. A Shack-Hartmann Wavefront sensor, a Deformable Mirror and other necessary optics hardware was combined together on a breadboard, and the control software was also implemented to form the feedback loop.https://ecommons.udayton.edu/stander_posters/1183/thumbnail.jp

Balancing the elicitation burden and the richness of expert input when quantifying discrete Bayesian networks

Structured expert judgment (SEJ) is a method for obtaining estimates of uncertain quantities from groups of experts in a structured way designed to minimize the pervasive cognitive frailties of unstructured approaches. When the number of quantities required is large, the burden on the groups of experts is heavy, and resource constraints may mean that eliciting all the quantities of interest is impossible. Partial elicitations can be complemented with imputation methods for the remaining, unelicited quantities. In the case where the quantities of interest are conditional probability distributions, the natural relationship between the quantities can be exploited to impute missing probabilities. Here we test the Bayesian intelligence interpolation method and its variations for Bayesian network conditional probability tables, called “InterBeta.” We compare the various outputs of InterBeta on two cases where conditional probability tables were elicited from groups of experts. We show that interpolated values are in good agreement with experts' values and give guidance on how InterBeta could be used to good effect to reduce expert burden in SEJ exercises

BARD : a structured technique for group elicitation of Bayesian networks to support analytic reasoning

In many complex, real-world situations, problem solving and decision making require effective reasoning about causation and uncertainty. However, human reasoning in these cases is prone to confusion and error. Bayesian networks (BNs) are an artificial intelligence technology that models uncertain situations, supporting better probabilistic and causal reasoning and decision making. However, to date, BN methodologies and software require (but do not include) substantial upfront training, do not provide much guidance on either the model building process or on using the model for reasoning and reporting, and provide no support for building BNs collaboratively. Here, we contribute a detailed description and motivation for our new methodology and application, Bayesian ARgumentation via Delphi (BARD). BARD utilizes BNs and addresses these shortcomings by integrating (1) short, high-quality e-courses, tips, and help on demand; (2) a stepwise, iterative, and incremental BN construction process; (3) report templates and an automated explanation tool; and (4) a multiuser web-based software platform and Delphi-style social processes. The result is an end-to-end online platform, with associated online training, for groups without prior BN expertise to understand and analyze a problem, build a model of its underlying probabilistic causal structure, validate and reason with the causal model, and (optionally) use it to produce a written analytic report. Initial experiments demonstrate that, for suitable problems, BARD aids in reasoning and reporting. Comparing their effect sizes also suggests BARD's BN-building and collaboration combine beneficially and cumulatively

Canagliflozin and renal outcomes in type 2 diabetes and nephropathy

BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to <90 ml per minute per 1.73 m2 of body-surface area and albuminuria (ratio of albumin [mg] to creatinine [g], >300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years